Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.
Multidrug-resistant (MDR) tuberculosis is a growing clinical and public-health concern. To evaluate existing evidence regarding treatment regimens for MDR tuberculosis, we used a Bayesian random-effects meta-analysis of the available therapeutic studies to assess how the reported proportion of patients treated successfully is influenced by differences in treatment regimen design, study methodology, and patient population. Successful treatment outcome was defined as cure or treatment completion. 34 clinical reports with a mean of 250 patients per report met the inclusion criteria. Our analysis shows that the proportion of patients treated successfully improved when treatment duration was at least 18 months, and if patients received directly observed therapy throughout treatment. Studies that combined both factors had significantly higher pooled success proportions (69%, 95% credible interval [CI] 64-73%) than other studies of treatment outcomes (58%, 95% CI 52-64%). Individualised treatment regimens had higher treatment success (64%, 95% CI 59-68%) than standardised regimens (54%, 95% CI 43-68%), although the difference was not significant. Treatment approaches and study methodologies were heterogeneous across studies. Many important variables, including patients' HIV status, were inconsistently reported between studies. These results underscore the importance of strong patient support and treatment follow-up systems to develop successful MDR tuberculosis treatment programmes.
Orenstein
Evan W
EW
Tugela Ferry Care and Research Collaboration, Tugela Ferry, KwaZulu-Natal, South Africa. Orenstein.Evan@gmail.com
Basu
Sanjay
S
Shah
N Sarita
NS
Andrews
Jason R
JR
Friedland
Gerald H
GH
Moll
Anthony P
AP
Gandhi
Neel R
NR
Galvani
Alison P
AP
D000995:Antitubercular Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D023801:Directly Observed Therapy; D006801:Humans; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
D000995:Antitubercular Agents